Clinical Trial Update: A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of PF-07284890 in patients with BRAF V600 mutant solid tumors, including those with brain involvement, has been terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Malignant Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• PF-07284890 (PF-07284890)

Snippet

Sponsor: Pfizer | Conditions: Malignant Melanoma, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2025-10-23